The Journal of Pediatrics
Volume 150, Issue 3 , Pages 229-234.e1, March 2007

Neurosensory Impairment after Surgical Closure of Patent Ductus Arteriosus in Extremely Low Birth Weight Infants: Results from the Trial of Indomethacin Prophylaxis in Preterms

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Department of Obstetrics and Gynecology, Royal Women’s Hospital, Melbourne, Australia; Department of Pediatrics, University of New Mexico School of Medicine, Albuquerque, NM; and Department of Pediatrics, Case Western Reserve University, Cleveland, OH.

Received 14 April 2006; received in revised form 5 October 2006; accepted 8 November 2006.

Objectives

To determine whether surgical closure of a patent ductus arteriosus (PDA) is a risk factor for bronchopulmonary dysplasia (BPD), severe retinopathy of prematurity (ROP), and neurosensory impairment in extremely low birth weight (ELBW) infants.

Study design

We studied 426 infants with a symptomatic PDA, 110 of whom underwent PDA ligation and 316 of whom received medical therapy only. All infants participated in the multicenter Trial of Indomethacin Prophylaxis in Preterms (TIPP) and were observed to a corrected age of 18 months.

Results

Of the 95 infants who survived after PDA ligation, 50 (53%) had neurosensory impairment, compared with 84 of the 245 infants (34%) who survived after receiving only medical therapy (adjusted odds ratio, 1.98; 95% CI, 1.18-3.30; P = .0093). BPD (adjusted odds ratio, 1.81; 95% CI, 1.09-3.03; P = .023) and severe ROP (adjusted odds ratio, 2.20; 95% CI, 1.19-4.07; P = .012) were also more common after surgical PDA closure.

Conclusions

PDA ligation may be associated with increased risks of BPD, severe ROP, and neurosensory impairment in ELBW infants.

Abbreviations: BPD, Bronchopulmonary dysplasia, ELBW, Extremely low birth weight, PDA, Patent ductus arteriosus, ROP, Retinopathy of prematurity, TIPP, Trial of Indomethacin Prophylaxis in Preterms

 

 Supported by the Medical Research Council of Canada MT-13288. US centers were supported in part by grants from the National Institute of Child Health and Human Development (D U10 HD21364, U10 HD27851, U10 HD21373, U10 HD27881; M01 RR 00997, U10 HD27880; M01 RR 00070, U10 HD21385, U10 HD27904, U10 HD34216). INDOCID P.D.A. was donated by Merck Frosst.

PII: S0022-3476(06)01108-5

doi:10.1016/j.jpeds.2006.11.039

Refers to article:

  • Patent Ductus Arteriosus: Evidence for and against Treatment

    Ronald I. Clyman, Nancy Chorne
    The Journal of Pediatrics March 2007 (Vol. 150, Issue 3, Pages 216-219)

The Journal of Pediatrics
Volume 150, Issue 3 , Pages 229-234.e1, March 2007